347 related articles for article (PubMed ID: 25114240)
1. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
[TBL] [Abstract][Full Text] [Related]
2. A previously undescribed tubulin binder.
Field JJ; Waight AB; Senter PD
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13684-5. PubMed ID: 25187564
[No Abstract] [Full Text] [Related]
3. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
[TBL] [Abstract][Full Text] [Related]
5. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
6. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
[TBL] [Abstract][Full Text] [Related]
7. Tubulins - the target for anticancer therapy.
Vindya NG; Sharma N; Yadav M; Ethiraj KR
Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
[TBL] [Abstract][Full Text] [Related]
8. New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism.
Pera B; Barasoain I; Pantazopoulou A; Canales A; Matesanz R; Rodriguez-Salarichs J; García-Fernandez LF; Moneo V; Jiménez-Barbero J; Galmarini CM; Cuevas C; Peñalva MA; Díaz JF; Andreu JM
ACS Chem Biol; 2013 Sep; 8(9):2084-94. PubMed ID: 23859655
[TBL] [Abstract][Full Text] [Related]
9. Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy.
Cao S; Dong YH; Wang DF; Liu ZP
Curr Med Chem; 2020; 27(27):4567-4576. PubMed ID: 32175831
[TBL] [Abstract][Full Text] [Related]
10. Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.
Khrapunovich-Baine M; Menon V; Yang CP; Northcote PT; Miller JH; Angeletti RH; Fiser A; Horwitz SB; Xiao H
J Biol Chem; 2011 Apr; 286(13):11765-78. PubMed ID: 21245138
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis of Microtubule Stabilization by Discodermolide.
Prota AE; Bargsten K; Redondo-Horcajo M; Smith AB; Yang CH; McDaid HM; Paterson I; Horwitz SB; Fernando Díaz J; Steinmetz MO
Chembiochem; 2017 May; 18(10):905-909. PubMed ID: 28207984
[TBL] [Abstract][Full Text] [Related]
12. Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules.
Wang Y; Benz FW; Wu Y; Wang Q; Chen Y; Chen X; Li H; Zhang Y; Zhang R; Yang J
Mol Pharmacol; 2016 Feb; 89(2):233-42. PubMed ID: 26660762
[TBL] [Abstract][Full Text] [Related]
13. Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization.
Khrapunovich-Baine M; Menon V; Verdier-Pinard P; Smith AB; Angeletti RH; Fiser A; Horwitz SB; Xiao H
Biochemistry; 2009 Dec; 48(49):11664-77. PubMed ID: 19863156
[TBL] [Abstract][Full Text] [Related]
14. A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin.
Menchon G; Prota AE; Lucena-Agell D; Bucher P; Jansen R; Irschik H; Müller R; Paterson I; Díaz JF; Altmann KH; Steinmetz MO
Nat Commun; 2018 May; 9(1):2106. PubMed ID: 29844393
[TBL] [Abstract][Full Text] [Related]
15. The high-resolution X-ray structure of vinca-domain inhibitors of microtubules provides a rational approach for drug design.
Chengyong W; Jinghong X; Yanyan W; Qing-Jie X; Lingling M; Yuyan L; Hai C; Qian L; Quan Z; Bo S; Yuxi W
FEBS Lett; 2021 Jan; 595(2):195-205. PubMed ID: 33220079
[TBL] [Abstract][Full Text] [Related]
16. Pironetin Binds Covalently to αCys316 and Perturbs a Major Loop and Helix of α-Tubulin to Inhibit Microtubule Formation.
Prota AE; Setter J; Waight AB; Bargsten K; Murga J; Diaz JF; Steinmetz MO
J Mol Biol; 2016 Jul; 428(15):2981-8. PubMed ID: 27395016
[TBL] [Abstract][Full Text] [Related]
17. A unique mode of microtubule stabilization induced by peloruside A.
Huzil JT; Chik JK; Slysz GW; Freedman H; Tuszynski J; Taylor RE; Sackett DL; Schriemer DC
J Mol Biol; 2008 May; 378(5):1016-30. PubMed ID: 18405918
[TBL] [Abstract][Full Text] [Related]
18. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
[TBL] [Abstract][Full Text] [Related]
19. Revisiting microtubule targeting agents: α-Tubulin and the pironetin binding site as unexplored targets for cancer therapeutics.
Coulup SK; Georg GI
Bioorg Med Chem Lett; 2019 Aug; 29(15):1865-1873. PubMed ID: 31130264
[TBL] [Abstract][Full Text] [Related]
20. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
